Barron’s has an article on this topic as well, coming to similar conclusions. It endorses Novartis (NVS), partly because it has a sizable toe in the generic drug business, which should benefit from a wave of expiring patents. See A Prescription for Profiting From Drug Stocks
BMY vs. MRK, update
Leave a Reply
You must be logged in to post a comment.